Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrosobenzene SCHEMBL27789607 | 0.92 | PARP1 (0.70) | PARP1CA12CA1CA2CA6 | |
| SCHEMBL29551821 | 0.91 | PARP1 (0.55) | PARP1POLBMEN1KMT2AMAPT | |
| SCHEMBL1565391 | 0.91 | PARP1 (0.55) | PARP1POLBMEN1KMT2AMAPT | |
| SCHEMBL31747489 | 0.85 | PARP1 (1.00) | PARP1CA12CA1CA2CA6 | |
| SCHEMBL161861 | 0.85 | PARP1 (1.00) | PARP1CA12CA1CA2CA6 | |
| Hydrochloric Acid SCHEMBL28324358 | 0.83 | PARP1 (0.95) | PARP1CA12CA1CA2CA6 | |
| Hydrochloric Acid SCHEMBL28287875 | 0.83 | PARP1 (0.95) | PARP1CA12CA1CA2CA6 | |
| SCHEMBL942655 | 0.79 | — | — | |
| SCHEMBL28617157 | 0.77 | PARP1 (0.57) | PARP1POLBMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL28890912 | 0.77 | CA12 (0.50) | PARP1CA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| EP-3877514-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | In8bio, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190076427-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2019-03-14 | — | — | US | disclosed |
| EP-3370774-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | King's College London (GB) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017077326-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2017-05-11 | — | — | WO | disclosed |
| EP-3047034-A1 | BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS | King's College London (GB) | 2016-07-27 | — | — | EP | disclosed |
| US-20160208339-A1 | BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS | KING'S COLLEGE LONDON (GB) | 2016-07-21 | — | — | US | disclosed |
| WO-2015040378-A1 | BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS | KING'S COLLEGE LONDON (GB) | 2015-03-26 | — | — | WO | disclosed |
| US-8143241-B2 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-03-27 | — | — | US | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | PARP1 5/4885CA12 4392/4885CA1 4179/4885 |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | PARP3, PARP11, GSK3A | PARP1 5/4885CA12 4392/4885CA1 4179/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PARP1 4/4885CA12 4641/4885CA1 4635/4885 |
| US-20190076427-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | PARP1 5/4885CA12 4392/4885CA1 4179/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | PARP1 3/4885CA12 2223/4885CA1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.